QKI Double Nickase Plasmid (h): sc-405082-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- QKI Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- QKI Double Nickase Plasmid (h) and QKI Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting QKI. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: QKI Antibody (N147/6): sc-517305
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
QKI Double Nickase Plasmid (h) | sc-405082-NIC | 20 µg | $410.00 |
QKI (quaking homolog) is an RNA-binding protein of the STAR family that regulates post-transcriptional gene expression through sequence-specific control of pre-mRNA splicing, mRNA export, stability, and localized translation. It is implicated in oligodendrocyte differentiation and myelination programs and influences cytoskeletal organization and cell fate decisions via coordinated regulation of neural and glial transcriptomes. QKI-dependent RNA processing integrates with signaling networks that shape developmental timing and stress responses, affecting pathways linked to cell proliferation and differentiation. Dysregulated QKI expression or isoform balance has been associated with neurodevelopmental and neuropsychiatric phenotypes and has been reported in multiple cancer contexts where altered RNA splicing and RNA metabolism contribute to disease biology.
QKI Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the QKI locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within QKI. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt QKI function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of QKI-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.